Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
Provided herein are compositions and methods for the treatment of tendinopathies, such as tenosynovitis, tendinosis or tendinitis, including Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis or “tennis elbow,” medial epicondylitis or “golfer's elbow,” plantar fasciitis, and rotator cuff tendinopathy, and in particular to methods for the treatment of tendinopathies by administering compositions comprising platelet-derived growth factor (PDGF).
1. A method of treating a tendinopathy comprising injecting into an affected site an effective amount of a solution comprising platelet-derived growth factor (PDGF) in a buffer, wherein the effective amount of the composition comprises about 75 μg to about 7,500 μg of PDGF per dose and wherein the affected site is an osseous-tendon junction.
2. The method of claim 1 , wherein the tendinopathy is a tendinosis.
3. The method of claim 1 , wherein the tendinopathy is a tendinitis.
4. The method of claim 1 , wherein the tendinopathy is a tenosynovitis.
5. The method of claim 1 , wherein the PDGF comprises PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, or PDGF-DD.
6. The method of claim 5 , wherein the PDGF comprises PDGF-BB.
7. The method of claim 6 , wherein the effective amount comprises about 500 μg to about 1,000 μg of PDGF-BB per dose.
8. The method of claim 6 , wherein the effective amount comprises about 5,000 μg to about 7,500 μg of PDGF-BB per dose.
9. The method of claim 6 , wherein the effective amount comprises about 450 μg to about 3000 μg of PDGF-BB per dose.
10. The method of claim 6 , wherein the effective amount comprises about 400 μg to about 1000 μg of PDGF-BB per dose.
11. The method of claim 6 , wherein the effective amount comprises about 500 μg to about 900 μg of PDGF-BB per dose.
12. The method of claim 6 , wherein the effective amount comprises about 600 μg to about 800 μg of PDGF-BB per dose.
13. The method of claim 6 , wherein the effective amount comprises about 650 μg to about 750 μg of PDGF-BB per dose.
14. The method of claim 5 , wherein the PDGF comprises recombinant human (rh) PDGF-BB.
15. The method of claim 1 , wherein the solution has a volume of about 1.0 to about 2.0 ml per dose.
16. The method of claim 1 , wherein the solution has a volume of about 1.5 ml per dose.
17. The method of claim 1 , wherein the buffer comprises phosphate-buffered saline, sodium acetate, ammonium acetate, acetic acid, citric acid, sodium citrate, tris(hydroxymethyl)aminoethane, N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 3-(N-morpholino) propanesulfonic acid, 2-(N-morpholino)ethanesulfonic acid, N-(2-acetamido)iminodiacetic acid, piperazine-N,N′-bis(2-ethanesulfonic acid), or N-(2-acetamido)-2-aminoethanesulfonic acid.
18. The method of claim 17 , wherein the buffer comprises sodium acetate.
19. The method of claim 1 , wherein the composition has a pH ranging from about 4.0 to about 7.0.
20. The method of claim 1 , wherein the tendinopathy comprises of Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis, medial epicondylitis, plantar fasciitis, or rotator cuff tendinopathy.
21. The method of claim 1 , wherein the tendinopathy is lateral epicondylitis.
22. The method of claim 1 , wherein the solution is administered in more than one dose.
23. The method of claim 1 , wherein the solution is injected using a peppering technique, wherein the needle is inserted into the affected osseous-tendon junction and multiple small injections are performed by withdrawing, redirecting and reinserting the needle into the osseous-tendon junction without the needle to emerging from the skin.
24. The method of claim 1 , wherein the solution is injected once a week for up to six months.
25. The method of claim 1 , wherein the solution is injected twice a month for up to six months.
26. The method of claim 1 , wherein the solution is injected once a month for up to six months.